The FDA has granted Israeli company Atox Bio’s tissue infection treatment AB103 fast track status. AB103 is designed to treat Necrotizing Soft Tissue Infections. The company will begin testing on 40 patients, suffering from the condition, which causes severe infection to the skin. There is currently no approved treatment for the condition.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israel And UAE Ink New Deal To Connect Ports Via Land Bridge
December 07, 2023

Dubbing Startup Unveils Innovative Fair Pay Plan For Voice Actors
December 07, 2023

Non-Profit Launches 10M Shekel Fund For Israeli Small Businesses
December 06, 2023

Amid War, Program Helps Open US Doors For 10 Israeli Startups
December 06, 2023
Facebook comments